News

News 06.10.2020 Zurich-Schlieren, Switzerland, October 6, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced supportive preclinical data from in vivo assessments of its DARPin® candidates targeting SARS-CoV-2. These candidates show robust activity in an...

News 06.10.2020 Schlieren (Zurich), Switzerland, October 6, 2020 – Kuros Biosciences today announced it will unveil new research on the role of osteoimmunology in bone formation in three presentations at the North American Spine Society (NASS) 2020 Annual Meeting, held virtually, October 6-9. Kuros is a leader in next generation bone graft technologies and...

News 05.10.2020 Schlieren (Zurich), Switzerland, October 5, 2020 – Kuros Biosciences BV, the Dutch subsidiary of Kuros Biosciences AG (SIX: KURN), today announced that MagnetOs Granules and MagnetOs Putty have both been entered on the Australian Register of Therapeutic Goods allowing marketing and sales on the Australian market.  Surgical Specialties Pty Ltd, Kuros’s...

News 01.10.2020 Schlieren (Zurich), Switzerland, October 1, 2020 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, will host an expert perspectives webinar on pioneering solutions for targeted and controlled bone healing on Wednesday, October 14, 2020 at 2pm Central European Time (CET). The call will feature a presentation...

News 25.09.2020 Zurich-Schlieren, Switzerland, September 24, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the presentation of preclinical findings supporting the mechanism of MP0317, a tri-specific DARPin® product candidate that includes binding domains for...